Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -8.78% is 99% above its 5-year average of -1506.58%, near the high end of its 5-year range (-33627.27%–70.13%).
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
-8.78%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
-1207.17%
NET PROFIT MARGIN AVG 5Y
-1506.58%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+99.27%
CURRENT VS 5Y AVG
+99.42%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 744 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Century Therapeutics, Inc.
Market Cap
$251.69M
Net Profit Margin
-8.78%
TTM Avg
0.00%
3Y Avg
-1207.17%
5Y Avg
-1506.58%
Market Cap
$256.72M
Net Profit Margin
-249.94%
TTM Avg
-1079.05%
3Y Avg
-1080.63%
5Y Avg
-787.30%
Market Cap
$248.86M
Net Profit Margin
-6138.26%
TTM Avg
-3731.55%
3Y Avg
-4082.97%
5Y Avg
-2721.98%
Market Cap
$258.23M
Net Profit Margin
-3.14%
TTM Avg
-28.33%
3Y Avg
-34.54%
5Y Avg
-25.62%
Market Cap
$244.52M
Net Profit Margin
-183.90%
TTM Avg
-383.83%
3Y Avg
-191.92%
5Y Avg
-127.94%
Market Cap
$245.85M
Net Profit Margin
62.87%
TTM Avg
27.75%
3Y Avg
54.97%
5Y Avg
-757.17%
Market Cap
$245.60M
Net Profit Margin
-29747.89%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$261.24M
Net Profit Margin
-6388.20%
TTM Avg
0.00%
3Y Avg
-1230.00%
5Y Avg
-820.00%
Market Cap
$263.05M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-2265.94%
5Y Avg
-2185.44%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | $251.69M | -8.78% | 0.00% | -1207.17% | -1506.58% |
| AC Immune S.A. (ACIU)vs › | $256.72M | -249.94% | -1079.05% | -1080.63% | -787.30% |
| Quantum-Si incorporated (QSI)vs › | $248.86M | -6138.26% | -3731.55% | -4082.97% | -2721.98% |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.23M | -3.14% | -28.33% | -34.54% | -25.62% |
| Invivyd, Inc. (IVVD)vs › | $244.52M | -183.90% | -383.83% | -191.92% | -127.94% |
| Q32 Bio Inc. (QTTB)vs › | $245.85M | 62.87% | 27.75% | 54.97% | -757.17% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $245.60M | -29747.89% | 0.00% | 0.00% | 0.00% |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | -6388.20% | 0.00% | -1230.00% | -820.00% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $263.05M | 0.00% | 0.00% | -2265.94% | -2185.44% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $242.34M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-13.8%
Net Profit Margin
-8.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 70.13% |
| 2024-12-31 | -864.44% |
| 2024-09-30 | -3947.66% |
| 2024-06-30 | -4047.60% |
| 2024-03-31 | -3282.11% |
| 2023-12-31 | -14700.75% |
| 2023-09-30 | -22108.11% |
| 2023-06-30 | -33627.27% |
| 2023-03-31 | -1817.67% |
| 2022-12-31 | -6081.00% |
| 2022-09-30 | -1382.60% |
| 2022-06-30 | -2219.77% |
| 2022-03-31 | -3545.65% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |